Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 20 years or older at informed consent~* Subjects with essential hypertension, who do not receive any antihypertensive drugs or receive calcium channel blocker, angiotensin converting enzyme ACE inhibitor, or angiotensin-II receptor blockade ARB during run-in period (Sitting systolic blood pressure SBP ≥ 140 mmHg and \< 180 mmHg, Sitting diastolic blood pressure DBP ≥ 90 mmHg and \< 110 mmHg, and mean 24hr SBP ≥ 130 and DBP ≥ 80 mmHg)~Exclusion Criteria:~* Secondary hypertension or malignant hypertension~* Diabetes mellitus with albuminuria~* Serum potassium level \< 3.5 or ≥ 5.1 mEq/L (≥ 4.8 mEq/L if receive ACE inhibitor, or ARB)~* Reversed day-night life cycle including overnight workers~* estimated glomerular filtration rate eGFR \< 60 mL/min/1.73 m\^2.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-3150 (Type: EXPERIMENTAL): CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).